Zofran (Ondansetron hydrochloride) injection.
About 30% of patients undergoing surgical procedures in the United States experience nausea and vomiting. Zofran injection has been used to control and eliminate nausea and vomiting in cancer patients since 1991. Clearance has been received from the Food and Drug Administration for marketing of Zofran injection for the prevention of postoperative nausea and vomiting, at a dose of 4 mg IV over 2 to 5 min. Zofran has been evaluated in clinical studies with good results in the reduction or prevention of postoperative nausea and vomiting with minimal adverse reactions.
Claussen
D W
DW
D006801:Humans; D009325:Nausea / Q000517:prevention & control*; D017294:Ondansetron / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control; D014839:Vomiting / Q000517:prevention & control*
D017294:Ondansetron